{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T19:11:25Z","timestamp":1775589085855,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,10,15]],"date-time":"2010-10-15T00:00:00Z","timestamp":1287100800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Targeted therapy approaches have been successfully introduced into the treatment of several cancers. The multikinase inhibitor Sorafenib has antitumor activity in solid tumors and its effects on acute lymphoblastic leukemia (ALL) cells are still unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>ALL cell lines (SEM, RS4;11 and Jurkat) were treated with Sorafenib alone or in combination with cytarabine, doxorubicin or RAD001. Cell count, apoptosis and necrosis rates, cell cycle distribution, protein phosphorylation and metabolic activity were determined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sorafenib inhibited the proliferation of ALL cells by cell cycle arrest accompanied by down-regulation of CyclinD3 and CDK4. Furthermore, Sorafenib initiated apoptosis by cleavage of caspases 3, 7 and PARP. Apoptosis and necrosis rates increased significantly with most pronounced effects after 96 h. Antiproliferative effects of Sorafenib were associated with a decreased phosphorylation of Akt (Ser473 and Thr308), FoxO3A (Thr32) and 4EBP-1 (Ser65 and Thr70) as early as 0.5 h after treatment. Synergistic effects were seen when Sorafenib was combined with other cytotoxic drugs or a mTOR inhibitor emphasizing the Sorafenib effect.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Sorafenib displays significant antileukemic activity<jats:italic>in vitro<\/jats:italic>by inducing cell cycle arrest and apoptosis. Furthermore, it influences PI3K\/Akt\/mTOR signaling in ALL cells.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1471-2407-10-560","type":"journal-article","created":{"date-parts":[[2010,10,15]],"date-time":"2010-10-15T18:17:39Z","timestamp":1287166659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells"],"prefix":"10.1186","volume":"10","author":[{"given":"Catrin","family":"Schult","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meike","family":"Dahlhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Ruck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandy","family":"Sawitzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Amoroso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Etro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aenne","family":"Glass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Fuellen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Boldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaf","family":"Wolkenhauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca Maria","family":"Neri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Freund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Junghanss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,15]]},"reference":[{"key":"2359_CR1","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/cncr.21776","volume":"106","author":"DA Thomas","year":"2006","unstructured":"Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H: Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006, 106: 1569-80. 10.1002\/cncr.21776.","journal-title":"Cancer"},{"key":"2359_CR2","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1002\/cncr.22631","volume":"109","author":"OG Ottmann","year":"2007","unstructured":"Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, Duhrsen U, Schmalzing M, Wunderle L, Binckebanck A, Hoelzer D: Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer. 2007, 109: 2068-76. 10.1002\/cncr.22631.","journal-title":"Cancer"},{"key":"2359_CR3","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","volume":"109","author":"M Vignetti","year":"2007","unstructured":"Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, Meloni G, Ambrosetti A, Quarta G, Pagano L, Rege-Cambrin G, Elia L, Bertieri R, Annino L, Foa R, Baccarani M, Mandelli F: Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Ad. Blood. 2007, 109: 3676-8. 10.1182\/blood-2006-10-052746.","journal-title":"Blood"},{"key":"2359_CR4","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.2174\/1381612023393026","volume":"8","author":"S Wilhelm","year":"2002","unstructured":"Wilhelm S, Chien D: BAY 43-9006: preclinical data. Curr Pharm Des. 2002, 8: 2255-7. 10.2174\/1381612023393026.","journal-title":"Curr Pharm Des"},{"key":"2359_CR5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","volume":"5","author":"S Wilhelm","year":"2006","unstructured":"Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006, 5: 835-44. 10.1038\/nrd2130.","journal-title":"Nat Rev Drug Discov"},{"key":"2359_CR6","doi-asserted-by":"publisher","first-page":"6861","DOI":"10.1038\/sj.onc.1208841","volume":"24","author":"C Yu","year":"2005","unstructured":"Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, Adjei AA: The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene. 2005, 24: 6861-9. 10.1038\/sj.onc.1208841.","journal-title":"Oncogene"},{"key":"2359_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/sj.leu.2404508","volume":"21","author":"D Auclair","year":"2007","unstructured":"Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y, Zhang X, Wilkie D, Burd A, Shi H, Rocks S, Gedrich R, Abriola L, Vasavada H, Lynch M, Dumas J, Trail PA, Wilhelm SM: Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia. 2007, 21: 439-45. 10.1038\/sj.leu.2404508.","journal-title":"Leukemia"},{"key":"2359_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/jnci\/djm328","volume":"100","author":"W Zhang","year":"2008","unstructured":"Zhang W, Konopleva M, Shi Y, McQueen T, Harris D, Ling X, Estrov Z, Quintas-Cardama A, Small D, Cortes J, Andreeff M: Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008, 100: 184-98. 10.1093\/jnci\/djm328.","journal-title":"J Natl Cancer Inst"},{"key":"2359_CR9","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64: 7099-109. 10.1158\/0008-5472.CAN-04-1443.","journal-title":"Cancer Res"},{"key":"2359_CR10","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1358\/dot.2005.41.12.937959","volume":"41","author":"D Strumberg","year":"2005","unstructured":"Strumberg D: Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc). 2005, 41: 773-84. 10.1358\/dot.2005.41.12.937959.","journal-title":"Drugs Today (Barc)"},{"key":"2359_CR11","doi-asserted-by":"publisher","first-page":"6567","DOI":"10.1182\/blood-2009-03-208298","volume":"113","author":"S Metzelder","year":"2009","unstructured":"Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, Eilers M, Enghofer E, Neubauer A, Burchert A: Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood. 2009, 113: 6567-71. 10.1182\/blood-2009-03-208298.","journal-title":"Blood"},{"key":"2359_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","volume":"26","author":"CI Bliss","year":"1939","unstructured":"Bliss CI: The toxicity of poisons applied jointly. ANNALS OF APPLIED BIOLOGY. 1939, 26: 585-615. 10.1111\/j.1744-7348.1939.tb06990.x.","journal-title":"ANNALS OF APPLIED BIOLOGY"},{"key":"2359_CR13","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1158\/1535-7163.MCT-06-0166","volume":"5","author":"E Buck","year":"2006","unstructured":"Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G: Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther. 2006, 5: 2676-84. 10.1158\/1535-7163.MCT-06-0166.","journal-title":"Mol Cancer Ther"},{"key":"2359_CR14","doi-asserted-by":"crossref","unstructured":"Grimme HL ARBTFMBWaSM: Combined Effects of Environmental Pollutants in Ecotoxicology: Biometrical Models as Concepts for Prediction and their Experimental Proof. UWSF - Z. Umweltchem. \u00d6kotox. 12: 226-234. 10.1007\/BF03038215.","DOI":"10.1007\/BF03038216"},{"key":"2359_CR15","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/sj.leu.2405098","volume":"22","author":"W Zhang","year":"2008","unstructured":"Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, Bornmann WG, McCubrey J, Cortes J, Andreeff M: Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia. 2008, 22: 808-18. 10.1038\/sj.leu.2405098.","journal-title":"Leukemia"},{"key":"2359_CR16","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1158\/1535-7163.MCT-09-0947","volume":"9","author":"F Yang","year":"2010","unstructured":"Yang F, Brown C, Buettner R, Hedvat M, Starr R, Scuto A, Schroeder A, Jensen M, Jove R: Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Mol Cancer Ther. 2010, 9: 953-62. 10.1158\/1535-7163.MCT-09-0947.","journal-title":"Mol Cancer Ther"},{"key":"2359_CR17","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/1535-7163.MCT-09-1004","volume":"9","author":"S Huang","year":"2010","unstructured":"Huang S, Sinicrope FA: Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol Cancer Ther. 2010, 9: 742-50. 10.1158\/1535-7163.MCT-09-1004.","journal-title":"Mol Cancer Ther"},{"key":"2359_CR18","doi-asserted-by":"publisher","first-page":"35217","DOI":"10.1074\/jbc.M506551200","volume":"280","author":"M Rahmani","year":"2005","unstructured":"Rahmani M, Davis EM, Bauer C, Dent P, Grant S: Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem. 2005, 280: 35217-27. 10.1074\/jbc.M506551200.","journal-title":"J Biol Chem"},{"key":"2359_CR19","doi-asserted-by":"publisher","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","volume":"66","author":"L Liu","year":"2006","unstructured":"Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C: Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5. Cancer Res. 2006, 66: 11851-8. 10.1158\/0008-5472.CAN-06-1377.","journal-title":"Cancer Res"},{"key":"2359_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10549-009-0714-5","volume":"124","author":"MA Bonelli","year":"2010","unstructured":"Bonelli MA, Fumarola C, Alfieri RR, La Monica S, Cavazzoni A, Galetti M, Gatti R, Belletti S, Harris AL, Fox SB, Evans DB, Dowsett M, Martin LA, Bottini A, Generali D, Petronini PG: Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Res Treat. 2010, 124: 79-88. 10.1007\/s10549-009-0714-5.","journal-title":"Breast Cancer Res Treat"},{"key":"2359_CR21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/jcp.21753","volume":"220","author":"P Ulivi","year":"2009","unstructured":"Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W: Role of RAF\/MEK\/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol. 2009, 220: 214-21. 10.1002\/jcp.21753.","journal-title":"J Cell Physiol"},{"key":"2359_CR22","first-page":"408","volume":"3","author":"H Chai","year":"2010","unstructured":"Chai H, Luo AZ, Weerasinghe P, Brown RE: Sorafenib downregulates ERK\/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line. Int J Clin Exp Pathol. 2010, 3: 408-15.","journal-title":"Int J Clin Exp Pathol"},{"key":"2359_CR23","doi-asserted-by":"publisher","first-page":"908","DOI":"10.4161\/cc.4.7.1796","volume":"4","author":"PK Vogt","year":"2005","unstructured":"Vogt PK, Jiang H, Aoki M: Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle. 2005, 4: 908-13.","journal-title":"Cell Cycle"},{"key":"2359_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1042\/bj20040167","volume":"380","author":"LP Van Der Heide","year":"2004","unstructured":"Van Der Heide LP, Hoekman MFM, Smidt MP: The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J. 2004, 380: 297-309. 10.1042\/BJ20040167.","journal-title":"Biochem J"},{"key":"2359_CR25","doi-asserted-by":"publisher","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","volume":"68","author":"V Serra","year":"2008","unstructured":"Serra V, Markman B, Scaltriti M, Eichhorn PJA, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J: NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008, 68: 8022-30. 10.1158\/0008-5472.CAN-08-1385.","journal-title":"Cancer Res"},{"key":"2359_CR26","doi-asserted-by":"publisher","first-page":"7410","DOI":"10.1038\/sj.onc.1209086","volume":"24","author":"EL Greer","year":"2005","unstructured":"Greer EL, Brunet A: FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene. 2005, 24: 7410-25. 10.1038\/sj.onc.1209086.","journal-title":"Oncogene"},{"key":"2359_CR27","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1038\/onc.2008.24","volume":"27","author":"Z Fu","year":"2008","unstructured":"Fu Z, Tindall DJ: FOXOs, cancer and regulation of apoptosis. Oncogene. 2008, 27: 2312-9. 10.1038\/onc.2008.24.","journal-title":"Oncogene"},{"key":"2359_CR28","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S0968-0004(03)00193-2","volume":"28","author":"MJ Cross","year":"2003","unstructured":"Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L: VEGF-receptor signal transduction. Trends Biochem Sci. 2003, 28: 488-94. 10.1016\/S0968-0004(03)00193-2.","journal-title":"Trends Biochem Sci"},{"key":"2359_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1479-5876-3-39","volume":"3","author":"KR Molhoek","year":"2005","unstructured":"Molhoek KR, Brautigan DL, Slingluff CLJ: Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med. 2005, 3: 39-10.1186\/1479-5876-3-39.","journal-title":"J Transl Med"},{"key":"2359_CR30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10549-008-0186-z","volume":"117","author":"S Sengupta","year":"2009","unstructured":"Sengupta S, Schiff R, Katzenellenbogen BS: Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells. Breast Cancer Res Treat. 2009, 117: 243-51. 10.1007\/s10549-008-0186-z.","journal-title":"Breast Cancer Res Treat"},{"key":"2359_CR31","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/nrc1169","volume":"3","author":"DL Stirewalt","year":"2003","unstructured":"Stirewalt DL, Radich JP: The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003, 3: 650-65. 10.1038\/nrc1169.","journal-title":"Nat Rev Cancer"},{"key":"2359_CR32","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1182\/blood-2003-07-2441","volume":"103","author":"SA Armstrong","year":"2004","unstructured":"Armstrong SA, Mabon ME, Silverman LB, Li A, Gribben JG, Fox EA, Sallan SE, Korsmeyer SJ: FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 2004, 103: 3544-6. 10.1182\/blood-2003-07-2441.","journal-title":"Blood"},{"key":"2359_CR33","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1182\/blood-2003-02-0418","volume":"103","author":"T Taketani","year":"2004","unstructured":"Taketani T, Taki T, Sugita K, Furuichi Y, Ishii E, Hanada R, Tsuchida M, Sugita K, Ida K, Hayashi Y: FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood. 2004, 103: 1085-8. 10.1182\/blood-2003-02-0418.","journal-title":"Blood"},{"key":"2359_CR34","first-page":"178","volume-title":"Hematology Am Soc Hematol Educ Program","author":"D Small","year":"2006","unstructured":"Small D: FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program. 2006, 178-84."},{"key":"2359_CR35","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00280-007-0639-9","volume":"61","author":"CH Takimoto","year":"2008","unstructured":"Takimoto CH, Awada A: Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol. 2008, 61: 535-48. 10.1007\/s00280-007-0639-9.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2359_CR36","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jhep.2009.03.028","volume":"51","author":"P Newell","year":"2009","unstructured":"Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, Savic R, Hoshida Y, Lim KH, Melgar-Lesmes P, Yea S, Peix J, Deniz K, Fiel MI, Thung S, Alsinet C, Tovar V, Mazzaferro V, Bruix J, Roayaie S, Schwartz M, Friedman SL, Llovet JM: Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol. 2009, 51: 725-33. 10.1016\/j.jhep.2009.03.028.","journal-title":"J Hepatol"},{"key":"2359_CR37","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ejca.2008.10.039","volume":"45","author":"H Richly","year":"2009","unstructured":"Richly H, Schultheis B, Adamietz IA, Kupsch P, Grubert M, Hilger RA, Ludwig M, Brendel E, Christensen O, Strumberg D: Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer. 2009, 45: 579-87. 10.1016\/j.ejca.2008.10.039.","journal-title":"Eur J Cancer"},{"key":"2359_CR38","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1182\/blood-2004-01-0388","volume":"104","author":"M Levis","year":"2004","unstructured":"Levis M, Pham R, Smith BD, Small D: In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood. 2004, 104: 1145-50. 10.1182\/blood-2004-01-0388.","journal-title":"Blood"},{"key":"2359_CR39","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1158\/1078-0432.CCR-07-4774","volume":"14","author":"Z Wang","year":"2008","unstructured":"Wang Z, Zhou J, Fan J, Qiu S, Yu Y, Huang X, Tang Z: Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res. 2008, 14: 5124-30. 10.1158\/1078-0432.CCR-07-4774.","journal-title":"Clin Cancer Res"},{"key":"2359_CR40","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.leukres.2006.08.001","volume":"31","author":"T Ikezoe","year":"2007","unstructured":"Ikezoe T, Nishioka C, Bandobashi K, Yang Y, Kuwayama Y, Adachi Y, Takeuchi T, Koeffler HP, Taguchi H: Longitudinal inhibition of PI3K\/Akt\/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk Res. 2007, 31: 673-82. 10.1016\/j.leukres.2006.08.001.","journal-title":"Leuk Res"},{"key":"2359_CR41","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/sj.leu.2404471","volume":"21","author":"T Haritunians","year":"2007","unstructured":"Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ, Koeffler HP: Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia. 2007, 21: 333-9. 10.1038\/sj.leu.2404471.","journal-title":"Leukemia"},{"key":"2359_CR42","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/leu.2008.144","volume":"22","author":"S Park","year":"2008","unstructured":"Park S, Chapuis N, Bardet V, Tamburini J, Gallay N, Willems L, Knight ZA, Shokat KM, Azar N, Viguie F, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D: PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia. 2008, 22: 1698-706. 10.1038\/leu.2008.144.","journal-title":"Leukemia"},{"key":"2359_CR43","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1158\/1535-7163.MCT-07-0155","volume":"6","author":"AB Hjelmeland","year":"2007","unstructured":"Hjelmeland AB, Lattimore KP, Fee BE, Shi Q, Wickman S, Keir ST, Hjelmeland MD, Batt D, Bigner DD, Friedman HS, Rich JN: The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Mol Cancer Ther. 2007, 6: 2449-57. 10.1158\/1535-7163.MCT-07-0155.","journal-title":"Mol Cancer Ther"},{"key":"2359_CR44","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1158\/1535-7163.MCT-06-0071","volume":"5","author":"T Ikezoe","year":"2006","unstructured":"Ikezoe T, Nishioka C, Tasaka T, Yang Y, Komatsu N, Togitani K, Koeffler HP, Taguchi H: The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther. 2006, 5: 2522-30. 10.1158\/1535-7163.MCT-06-0071.","journal-title":"Mol Cancer Ther"},{"key":"2359_CR45","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1182\/blood-2007-03-080796","volume":"111","author":"J Tamburini","year":"2008","unstructured":"Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D: Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase\/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood. 2008, 111: 379-82. 10.1182\/blood-2007-03-080796.","journal-title":"Blood"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-560.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-10-560\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-560","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-560.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T23:24:54Z","timestamp":1636673094000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-10-560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,15]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["2359"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-10-560","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,15]]},"assertion":[{"value":"27 May 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"560"}}